What is Integrium?
Founded in 1998 and headquartered in Tustin, California, with additional offices in Cedar Knolls, New Jersey, Integrium operates as a full-service clinical proof-of-concept firm. The company specializes in assisting micro-cap, small-cap, and privately held biotechnology firms, both in the generic and innovator spaces, to achieve critical clinical data milestones and enhance their capital standing. Integrium's therapeutic expertise spans a broad range of areas, including Cardiovascular, Metabolic, Renal, Inflammatory, Dermatology, Wound Healing, Gene Therapy, and Orphan Diseases. The firm also possesses secondary specialties in Schedule 2 drugs and Oncology, positioning it as a versatile partner in clinical development.
How much funding has Integrium raised?
Integrium has raised a total of $956K across 2 funding rounds:
Debt
$350K
Debt
$606K
Debt (2020): $350K with participation from PPP
Debt (2021): $606K led by PPP
Key Investors in Integrium
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Integrium?
The recent major strategic investment provides Integrium with the necessary resources to accelerate its growth trajectory. This capital infusion is expected to fuel further development of its clinical services, potentially expanding its therapeutic focus areas or enhancing its operational capabilities. The company's established track record in supporting biotech firms through critical data generation and capital attainment suggests a strategic focus on solidifying its market position and potentially exploring new avenues for innovation and partnership within the life sciences industry.
See full Integrium company page
